Contract Pharma Staff01.12.21
Parexel, a provider of drug development servicess from clinical through commercialization, has completed the separation of its Parexel Informatics and Medical Imaging business. The strategic move aims to simplify and streamline Parexel’s business strategy and customer relationships while positioning both organizations for continued, long-term growth. As part of the separation, Parexel Informatics will become Calyx.
Parexel will continue to leverage Calyx’s Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), Interactive Response Technology (IRT) and Regulatory Information Management (RIM) solutions moving forward as part of the company’s clinical development offerings. Calyx will be privately held by the same ownership group that has owned Parexel since 2017.
"This announcement marks a significant milestone as we further position Parexel to expect accelerated growth and performance as a top-tier CRO," said Jamie Macdonald, Chief Executive Officer of Parexel. "We believe the separation will provide Calyx the opportunity to prioritize investments in technology development, customer delivery and customer relationships while enabling the Parexel corporate business to strengthen its focus on the delivery of innovative clinical development solutions that reinforce our patients-first focus and advance world health.”
Calyx will be led by Chief Executive Officer Gavin Nichols and the company will be headquartered in Nottingham, UK, and Durham, NC. The new organization will employ approximately 2,300 employees.
Parexel will continue to leverage Calyx’s Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), Interactive Response Technology (IRT) and Regulatory Information Management (RIM) solutions moving forward as part of the company’s clinical development offerings. Calyx will be privately held by the same ownership group that has owned Parexel since 2017.
"This announcement marks a significant milestone as we further position Parexel to expect accelerated growth and performance as a top-tier CRO," said Jamie Macdonald, Chief Executive Officer of Parexel. "We believe the separation will provide Calyx the opportunity to prioritize investments in technology development, customer delivery and customer relationships while enabling the Parexel corporate business to strengthen its focus on the delivery of innovative clinical development solutions that reinforce our patients-first focus and advance world health.”
Calyx will be led by Chief Executive Officer Gavin Nichols and the company will be headquartered in Nottingham, UK, and Durham, NC. The new organization will employ approximately 2,300 employees.
